[1] Mathieu J, RuoholaBaker H. Regulation of stem cell populations by microRNAs[J]. Adv Exp Med Biol, 2013, 786: 329-351. [2] Di Leva G, Croce CM. Roles of small RNAs in tumor formation[J]. Trends Mol Med, 2010, 16(6): 257-267. [3] Viswanathan SR, Daley GQ. Lin28: A microRNA regulator with a macro role[J]. Cell, 2010, 140(4): 445-449. [4] Boyerinas B, Park SM, Hau A, et al. The role of let-7 in cell differentiation and cancer[J]. Endocr Relat Cancer, 2010, 17(1): F19-36. [5] Roush S, Slack FJ. The let-7 family of microRNAs[J]. Trends Cell Biol, 2008, 18(10): 505-516. [6] Heo I, Joo C, Cho J, et al. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA[J]. Mol Cell, 2008, 32(2): 276-284. [7] Piskounova E, Polytarchou C, Thornton JE, et al. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms[J]. Cell, 2011, 147(5): 1066-1079. [8] Rybak A, Fuchs H, Smirnova L, et al. A feedback loop comprising lin-28 and let-7 controls prelet-7 maturation during neural stemcell commitment[J]. Nat Cell Biol, 2008, 10(8): 987-993. [9] Yamanaka S. Pluripotency and nuclear reprogramming[J]. Philos Trans R Soc Lond B Biol Sci, 2008, 363(1500):2079-2087. [10] Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28[J]. Science, 2008, 320(5872): 97-100. [11] Li X, Zhang J, Gao L, et al. MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit[J]. Cell Death Diffe, 2012, 19(3): 378-386. [12] Yang X, Lin X, Zhong X, et al. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells[J]. Cancer Res, 2010, 70(22): 9463-9472. [13] Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a subpopulation of stem cell-like cells in ovarian cancer[J]. Oncogene, 2010, 29(14): 2153-2159. [14] Ma W, Ma J, Xu J, et al. Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment[J]. Cell Cycle, 2013, 12(1): 88-97. [15] Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies[J]. Nat Genet, 2009, 41(7): 843-848. [16] Chang TC, Zeitels LR, Hwang HW, et al. Lin-28B transactivation is necessary for Mycmediated let-7 repression and proliferation[J]. Proc Natl Acad Sci USA, 2009, 106(9): 3384-3389. [17] Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let7 MicroRNA, and IL6 links inflammation to cell transformation[J]. Cell, 2009, 139(4): 693-706. [18] Saiki Y, Ishimaru S, Mimori K, et al. Comprehensive analysis of the clinical significance of inducing pluripotent stemnessrelated gene expression in colorectal cancer cells[J]. Ann Surg Oncol, 2009, 16(9): 2638-2644. [19] King CE, Cuatrecasas M, Castells A, et al. LIN28B promotes colon cancer progression and metastasis[J]. Cancer Res, 2011, 71(12): 4260-4268. [20] Hamano R, Miyata H, Yamasaki M, et al. High expression of Lin28 is associated with tumour aggressiveness and poor prognosis of patients in oesophagus cancer[J]. Br J Cancer, 2012, 106(8): 1415-1423. [21] DangiGarimella S, Yun J, Eves EM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7[J]. EMBO J, 2009, 28(4): 347-358. [22] Lv K, Liu L, Wang L, et al. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let7a miRNA in breast cancer cells[J]. PLoS One, 2012, 7(7): e40008. [23] Jeong SH, Wu HG, Park WY. LIN28B confers radioresistance through the posttranscriptional control of KRAS[J]. Exp Mol Med, 2009, 41(12): 912-918. [24] Besancon R, ValsesiaWittmann S, Puisieux A, et al. Cancer stem cells: the emerging challenge of drug targeting[J]. Curr Med Chem, 2009, 16(4): 394-416. [25] Thornton JE, Gregory RI. How does Lin28 let7 control development and disease?[J]. Trends Cell Biol, 2012, 22(9): 474-482. |